PMID- 35355433
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20230916
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 13
IP  - 9
DP  - 2022 May
TI  - A global perspective in second-line treatment patterns for patients with advanced 
      esophageal squamous cell carcinoma.
PG  - 1240-1257
LID - 10.1111/1759-7714.14334 [doi]
AB  - BACKGROUND: Esophageal cancer is a highly prevalent cancer associated with low 
      survival, especially among those with advanced disease. Second-line (2L) 
      treatment patterns and related clinical outcomes of patients with advanced 
      esophageal squamous cell carcinoma (advESCC) treated in routine clinical care 
      were examined globally and regionally. METHODS: A retrospective, 
      noninterventional study collected physician-provided chart data of patients aged 
      >/=20 years receiving either 2L active systemic therapy or BSC following first-line 
      active therapy for advESCC from 11 countries in Asian and Western regions 
      (September-October 2018). Bivariate analyses examined treatment and outcomes by 
      region. RESULTS: AdvESCC patients (Asia = 192; West = 195) were examined, of 
      which 58.1% (Asia n = 101; West n = 124) received active systemic therapy. While 
      regional differences in tumor classification and staging at diagnosis were 
      observed with less advanced tumors in Asia, no regional differences for these 
      characteristics at 2L initiation were reported. Both taxane- and nontaxane-based 
      therapies were used as 2L therapy among Asian and Western patients, although more 
      western than Asian patients received immuno- or targeted therapies (17.0% vs. 
      3.0%; p = 0.001). Alopecia (10.7%), neutropenia (9.3%), and fatigue (9.3%) were 
      the most-commonly reported adverse events (AEs) in both regions. Significantly 
      higher 2L AE-related emergency room visits (Asia = 22.5% vs. West = 8.0%; 
      p < 0.001) and hospitalizations (Asia = 25.9 +/- 31.2 vs. West = 4.7 +/- 7.0, 
      p < 0.001) were observed in Asian than in Western patients. No regional 
      differences were reported for response to 2L treatment or the percent of patients 
      who received third-line treatment/died. CONCLUSIONS: While regional variations 
      were observed throughout the course of a patient's advESCC journey, disease 
      response and treatment outcomes were similar.
CI  - (c) 2022 Cerner Enviza. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Jaffe, Dena H
AU  - Jaffe DH
AUID- ORCID: 0000-0001-5134-037X
AD  - RWE, Cerner Enviza, Jerusalem, Israel.
FAU - Gricar, Joseph
AU  - Gricar J
AD  - WWHEOR, Bristol-Myers Squibb, Princeton, New Jersey, USA.
FAU - DeCongelio, Marc
AU  - DeCongelio M
AD  - Research and Consulting, Cerner Enviza, New York, New York, USA.
FAU - Mackie, deMauri S
AU  - Mackie DS
AD  - RWE, Cerner Enviza, New York, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220330
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Esophageal Neoplasms/pathology
MH  - *Esophageal Squamous Cell Carcinoma/drug therapy
MH  - Humans
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC9058306
OTO - NOTNLM
OT  - Esophageal cancer
OT  - advanced ESCC
OT  - healthcare resource utilization
OT  - second-line
OT  - treatment patterns
COIS- JG is an employee of Bristol-Myers Squibb. DHJ, MD, and MDS are employed at 
      Cerner Enviza, which was paid by Bristol-Myers Squibb to conduct the study.
EDAT- 2022/04/01 06:00
MHDA- 2022/05/04 06:00
PMCR- 2022/05/01
CRDT- 2022/03/31 05:15
PHST- 2022/01/10 00:00 [revised]
PHST- 2021/10/21 00:00 [received]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/04/01 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
PHST- 2022/03/31 05:15 [entrez]
PHST- 2022/05/01 00:00 [pmc-release]
AID - TCA14334 [pii]
AID - 10.1111/1759-7714.14334 [doi]
PST - ppublish
SO  - Thorac Cancer. 2022 May;13(9):1240-1257. doi: 10.1111/1759-7714.14334. Epub 2022 
      Mar 30.